ONCO

Onconetix Inc. Common Stock (ONCO)

Stock · NASDAQ · Health Care

$0.4772as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 3, 2026

ONCO Included in 12 Health Care Stocks Moving Intraday. On Monday and Tuesday, ONCO was listed among 12 health‑care stocks that saw notable intraday price swings. The moves were accompanied by higher than usual trading volume, indicating increased interest. The stock’s RSI sits near 47, suggesting it is neither overbought nor oversold. These developments may influence short‑term trading activity for ONCO.

Active signals

High Beta72.0%
200 SMA Touch0.0%
Resistance level
$0.708313
Industry
Biotechnology: Pharmaceutical Preparations

What ONCO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Bollinger Band Breakdown18-18.4%22%
Bollinger Band Breakout14-20.3%14%
Volume Spike7-44.4%0%
200-Day Moving Average TouchActive now3-20.9%0%
Any 20-session window (baseline)-14.7%24%

Computed by MarketWall from daily closing prices since December 5, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About ONCO

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Im…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
2

Fundamentals

1-day range
$0.5331$0.5537
Market cap
$3.34M
P/E (trailing)
0.00
P/E (forward)
-0.64
EPS (trailing)
$-200.08
Dividend yield
—
Beta
2.60
Avg. volume
2.91M
52-week range
$0.535$200

How Onconetix Inc. Common Stock Makes Money

Where the revenue actually goes — FY2024 annual results

market-wall.comTotalRevenue$2.52MSG&A$11.23M (445%)Cost of Revenue$1.47M (58%)R&D$154.4K (6%)ONCO

Source: 10-K filed Jun 2, 2025 · via SEC EDGAR / Finnhub

Gross Profit$1.06M(42%)
Operating Income-$56.49M(-2238%)

Onconetix Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • ONCO
    Onconetix Inc. Common Stock
    $0.479
    ▼ 12.59%
    Market cap $3.34MP/E 0.00
    $0.535$200
  • PRFX
    PRF Technologies Ltd. Ordinary Shares
    $0.781
    ▼ 7.68%
    Market cap $3.35MP/E —
    $0.8099$7.95
  • SXTP
    60 Degrees Pharmaceuticals Inc. Common Stock
    $0.855
    ▼ 4.89%
    Market cap $3.28MP/E —
    $0.835$8.62
  • XRTX
    XORTX Therapeutics Inc. Common Shares
    $1.24
    ▼ 12.68%
    Market cap $3.51MP/E —
    $2.42$9.85
  • RDHL
    Redhill Biopharma Ltd. American Depositary Shares
    $0.48
    ▼ 3.81%
    Market cap $3.53MP/E Infinity
    $0.4351$2.14
  • SBFM
    Sunshine Biopharma Inc. Common Stock
    $0.222
    ▼ 3.48%
    Market cap $2.97MP/E —
    $0.4117$24.3
  • SPRC
    SciSparc Ltd. Ordinary Shares
    $1.7
    ▼ 15.00%
    Market cap $3.85MP/E —
    $1.63$43.65

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
201.5K
Disposed
198.0K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.